TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02780518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo
Description: Applying high flow nasal oxygen
Study: NCT02650713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
Study: NCT00983645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: Cyclosporine (Neoral) starting dose 3mg/kg PO BID
Study: NCT01676103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tyrosine
Description: Tyrosine supplementation (500 mg 2 x daily) for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator:Sugar Pill
Description: Placebo sugar pills (2x daily
Study: NCT03905837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous or paravertebral lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous or paravertebral lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: intravenous remifentanil
Study: NCT01618786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmartCell flooring
Description: SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plywood flooring
Description: Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
Study: NCT01823471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of I-scan in the detection of polyps in HNPCC
Description: Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The use of I-scan in the detection of polyps in HNPCC
Description: Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
Study: NCT02114619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of I-131
Description: We wil administer 100 micro currie of iodine per thyroid gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate dose
Description: We will administer 150 micro currie of iodine per thyroid gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose
Description: We will administer 200 micro currie of iodine per thyroid gram
Study: NCT02630563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine will be administered as per center practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
Study: NCT04812184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tape Face Mask
Description: Adding tape to face mask
Study: NCT02104076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolution® Biliary Stent-Fully Covered
Description: Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
Study: NCT01649882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US ETT (ultrasound endotracheal tube)
Description: Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
Study: NCT02558842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Strategy
Description: Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit.
Study: NCT00379561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSA-Activated PSA-PAH1
Study: NCT01799447

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early intervention
Description: Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
Study: NCT01495052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: organic naked oat with whole germ (ONOG)
Description: The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: organic naked oat with whole germ (ONOG)
Description: The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
Study: NCT01676051

Intervention type: OTHER
Intervention: Skin culture
Description: Culture swab used to culture skin adjacent to incision

Intervention type: OTHER
Intervention: Skin culture
Description: Culture swab used to culture skin adjacent to incision

Intervention type: OTHER
Intervention: Skin culture
Description: Culture swab used to culture skin adjacent to incision
Study: NCT02195635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 500 mg telotristat etiprate

Intervention type: DRUG
Group type: OTHER
Intervention: Telotristat etiprate
Description: 500 mg telotristat etiprate

Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide acetate
Description: 200 µg octreotide acetate three times daily
Study: NCT03189212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Visit
Description: Routine 6-month follow up appointment at the NYULMC transplant center

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Visit
Description: TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
Study: NCT01703390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modifiedFOLFOX6 + Cetuximab
Study: NCT03423212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just Do You
Description: Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services \& how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
Study: NCT03788161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Virtual Reality
Description: Participants will receive a distraction by playing a game of virtual reality with a 3D application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Virtual Reality
Description: Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
Study: NCT03296969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section
Description: All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section
Description: All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle approximation
Description: aprroximation of the lower parts of rectus abdomius muscles during cesarean section
Study: NCT01255072

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
Study: NCT01131559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: Oral; 20-70mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Oral; 20-70mg/day
Study: NCT04226300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Description: A transversus abdominis nerve block will be placed laparoscopically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: A transversus abdominis nerve block will be place by ultrasound
Study: NCT05856253

Intervention type: PROCEDURE
Intervention: Enhanced recovery program
Description: Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
Study: NCT01519817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301 (Yeast Brachyury Vaccine)
Description: GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
Study: NCT01089842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Usual care
Description: Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
Study: NCT04020653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferrous citrate (SFC) 472 mg QD
Description: SFC 118 mg capsules will be given to the patients as 472 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination (ACT)
Description: Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination (ACT)
Description: Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemisinin-based combination (ACT)
Description: Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferrous citrate (SFC) 236 mg BID
Description: SFC 118 mg capsules will be given to the patients as 236 mg BID
Study: NCT02650713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower.
Study: NCT01151306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20mg once daily (in the evening) for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tablet
Description: One tablet taken each evening for 6 weeks
Study: NCT00612911

Intervention type: OTHER
Intervention: Cell therapy
Description: bone marrow mononuclear cell
Study: NCT03784391

Intervention type: DRUG
Intervention: Lampit (Nifurtimox, BAYA2502)
Description: Nifurtimox is a drug already approved in some South American countries since more than 45 years
Study: NCT02653157

Intervention type: OTHER
Intervention: MDR-GNB
Study: NCT04230369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based Internet-CBT
Description: Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
Study: NCT00281697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard chemotherapy
Description: Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle.
Study: NCT03498729

Intervention type: OTHER
Intervention: Peripheral Blood Sample
Description: 30mL peripheral whole blood sample

Intervention type: OTHER
Intervention: Peripheral Blood Sample
Description: 30mL peripheral whole blood sample

Intervention type: OTHER
Intervention: Peripheral Blood Sample
Description: 30mL peripheral whole blood sample

Intervention type: OTHER
Intervention: Peripheral Blood Sample
Description: 30mL peripheral whole blood sample
Study: NCT01553565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold polypectomy
Description: All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold polypectomy
Description: All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
Study: NCT04438408

Intervention type: OTHER
Intervention: questionaires
Description: patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
Study: NCT03293745

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face CBT-I (F2F)
Description: CBT-I delivered in-person by the therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine CBT-I (TM)
Description: CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.